PGGM Investments

Position in REGN — Regeneron Pharmaceuticals, Inc.

CIK 1472190 ZEIST, P7

Position in REGN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$71,534,101

+$71,289 QoQ

Shares Held

92,584

0.0% QoQ

Ownership

0.088%

of shares outstanding

% of Portfolio

1.25%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

19 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

PGGM Investments holds $123,757,199 across 2 Biotechnology names. REGN ranks #1 (57.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)	Open
1	REGN	Regeneron Pharmaceuticals, Inc. This page	92,584	$71,534,101
2	ARGX	Argenx SE	71,514	$52,223,098

19 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$71,534,101	92,584	0.0%	Shares	Sole	2026-05-15
2025-12-31	$71,462,812	92,584	0.0%	Shares	Sole	2026-02-09
2025-09-30	$52,057,205	92,584	+9.7%	Shares	Sole	2025-10-28
2025-06-30	$44,308,425	84,397	+159.7%	Shares	Sole	2025-07-18
2025-03-31	$20,610,572	32,497	0.0%	Shares	Sole	2025-05-12
2024-12-31	$23,148,588	32,497	+24.0%	Shares	Sole	2025-02-10
2024-09-30	$27,539,334	26,197	-20.0%	Shares	Sole	2024-11-13
2024-06-30	$34,398,109	32,728	-9.2%	Shares	Sole	2024-07-16
2024-03-31	$34,677,552	36,029	0.0%	Shares	Sole	2024-05-24
2023-12-31	$31,643,910	36,029	-36.4%	Shares	Sole	2024-02-05
2023-09-30	$46,614,100	56,642	+3.7%	Shares	Sole	2023-11-08
2023-06-30	$39,259,588	54,638	+8.8%	Shares	Sole	2023-08-07
2023-03-31	$41,249,477	50,202	+5.1%	Shares	Sole	2023-05-11
2022-12-31	$34,460,526	47,763	+6.9%	Shares	Sole	2023-02-13
2022-09-30	$30,774,578	44,674	+408.2%	Shares	Sole	2022-11-10
2022-03-31	$6,139,810	8,791	0.0%	Shares	Sole	2022-04-25
2021-12-31	$5,551,692	8,791	-87.3%	Shares	Sole	2022-01-28
2020-09-30	$38,873,362	69,444	+44.8%	Shares	Sole	2020-10-20
2020-06-30	$29,907,135	47,955	—	Shares	Sole	2020-07-17
No filing history on record for this holder in this stock.